← Back to Search

PD-1 Inhibitor

LYT-200 + Chemotherapy/Tislelizumab for Cancer

Phase 1 & 2
Research Sponsored by PureTech
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients who have received at least one prior line of systemic therapy for metastatic or locally advanced disease, and/or have a tumor type for which there are no available standard of care options
ECOG performance status 0-1
Screening 3 weeks
Treatment Varies
Follow Up approximately 1 year
Awards & highlights

Study Summary

This trial is testing a new drug, LYT-200, for safety and effectiveness in treating patients with metastatic solid tumors.

Who is the study for?
Adults with certain advanced cancers (like head and neck, pancreatic, bladder, or colorectal) that can't be removed by surgery. They should have measurable disease and be able to undergo biopsies. Prior immunotherapy is okay if they meet response criteria. Must not be pregnant and agree to contraception.Check my eligibility
What is being tested?
The trial tests LYT-200 alone or combined with chemotherapy or Tislelizumab in patients with metastatic solid tumors. It's an early-phase study assessing safety, how the body processes the drugs, and their effectiveness against cancer.See study design
What are the potential side effects?
Possible side effects include typical reactions to immunotherapies such as fatigue, skin reactions, digestive issues; specific side effects of LYT-200 are not detailed but may align with common chemotherapy or immunotherapy-related complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I've had at least one treatment for my advanced cancer or have a cancer with no standard treatment options.
I am fully active or can carry out light work.
I have waited the required time since my last cancer treatment before starting LYT-200.
My cancer type has been confirmed by specific lab tests.
I am willing and able to have biopsies before, during, and after treatment.
My blood and organ tests meet the required health standards.
I have been on bisphosphonate treatment before this clinical trial.
I understand the study details and am willing to sign the consent form.
I am 18 years or older and not pregnant.
My cancer cannot be removed by surgery and has spread.
My cancer is advanced and cannot be removed by surgery, and I've had various treatments.
I have previously received immunotherapy.
I have never been treated with gemcitabine.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Part 1: Incidence of Dose Limiting Toxicities [Tolerability]
Part 1: Incidence of Treatment-Emergent Adverse Events [Safety]
Part 2: PFS or ORR [Preliminary Efficacy]
Secondary outcome measures
Part 1: Pharmacodynamics (PD) of LYT- 200
Part 1: Pharmacokinetic (PK) profile of LYT-200: Area Under the Curve [AUC]
Part 1: Pharmacokinetic (PK) profile of LYT-200: Maximum Plasma Concentration [Cmax]
+1 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: Part 2Experimental Treatment3 Interventions
LYT-200 combination dose expansion in select metastatic solid tumors based on outcomes of Part 1
Group II: Part 1 single agent dose escalationExperimental Treatment1 Intervention
LYT-200 in metastatic solid tumors
Group III: Part 1 combination agents dose expansionExperimental Treatment3 Interventions
LYT-200 in combination with chemotherapy or Tislelizumab in select metastatic solid tumors
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3

Find a Location

Who is running the clinical trial?

PureTechLead Sponsor
5 Previous Clinical Trials
751 Total Patients Enrolled
Aleksandra Filipovic, MD, Ph.D.Study DirectorPureTech Health

Media Library

Anti-PD-1 (PD-1 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04666688 — Phase 1 & 2
Head and Neck Cancers Research Study Groups: Part 1 combination agents dose expansion, Part 2, Part 1 single agent dose escalation
Head and Neck Cancers Clinical Trial 2023: Anti-PD-1 Highlights & Side Effects. Trial Name: NCT04666688 — Phase 1 & 2
Anti-PD-1 (PD-1 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04666688 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

How old are they?
What site did they apply to?
Mayo Clinic
What portion of applicants met pre-screening criteria?
Met criteria
~7 spots leftby Sep 2024